According to a research report published this morning, Citi has initiated Supernus Pharmaceuticals SUPN with a Neutral rating and $6 PT.
In the report, Citi said, "Our PT is based on a DCF value of $6/share. Our upside & downside Trokendi market share scenarios show a DCF value of >$9 & >$3, respectively. Our High Risk rating reflects the need for additional capital to execute its commercial plans on its extended release (ER) AED's."
Supernus Pharmaceuticals closed Friday at $5.98.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in